We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein Found to Block Pancreatic Tumor Growth

By Biotechdaily staff writers
Posted on 19 Oct 2006
Researchers have found that when the human protein PNC-28 is administered to pancreatic tumor cells in animals, the tumors are destroyed. More...


Matthew R. Pincus, M.D., Ph.D., professor of pathology at the State University of New York (SUNY) Downstate Medical Center (Brooklyn NY, USA) and chairman of pathology and laboratory medicine at the Brooklyn Veterans Administration (VA) Hospital (NY, USA) said, "The results are very encouraging. PNC-28 may be an effective agent in treating cancers, especially if delivered directly to the tumor.”

PNC-28 is a p53 peptide, a naturally occurring human protein known to inhibit tumor growth. The researchers earlier discovered that PNC-28 triggers death of a range of human tumor cell lines, including a pancreatic cancer cell line, while not harming healthy cells.

The investigators have now given PNC-28 to laboratory animals to assess its ability to block the growth of pancreatic cancer cells. When administered over a two-week period in the peritoneal cavities of mice containing simultaneously transplanted tumors, PNC-28 caused complete destruction of these tumors. When delivered concurrently with tumor implantation, PNC-28 completely blocked tumor growth during the two-week period of administration and two weeks post-treatment, followed by weak tumor growth that leveled off at low tumor sizes.

Furthermore, according to Josef Michl, M.D., associate professor of pathology at SUNY Downstate, "When administered from a site distant from the tumor, PNC-28 still caused a decrease in tumor size. This tumor growth was significantly slower than growth in the presence of a control peptide.”

Dr. Pincus also reported that this peptide and its parent peptide, called PNC-27, are deadly to a wide variety of human cancer cells, in addition to pancreatic cancer, including colon, breast, cervical, and bone (osteogenic sarcoma) cancers. These peptides destroy cancer cells that do not even contain native p53 protein and therefore appear to have a wide applicability in treating a variety of human cancers.

The research was published in the October 1, 2006, issue of the International Journal of Cancer.



Related Links:
State University of New York (SUNY) Downstate Medical Center

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Hematology Consumables
Bioblood Devices
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.